Kaynaklar
- Steimer W. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit 2010; 32: 381–386.
- Jain KK. Role of biomarkers in personalized medicine. In Textbook of Personalized Medicine, Jain KK (editor), Springer, 2009, p. 59–68.
- Evers K. Personalized medicine in psychiatry: ethical challenges and opportunities. Dialogues Clin Neurosci 2009; 11: 427–434.
- Ozdemir V, Kashuba ADM, Basile VS, Kennedy JL. Pharmacogenetics of psychotropic drug metabolism. In Pharmacogenetics of Psychotropic Drugs, Lerer B (editor), Cambridge University Press, 2004, p. 157–180.
- Dahl ML, Scordo MG. Cytochromes P450. In Psychopharmacogenetics, Gorwood P, Hamon M.(editors), New York: Springer Science, 2006, p. 443–479.
- Plesnicar BK. Personalized antipsychotic treatment: the adverse effects perspectives. Psychiatr Danub 2010; 22: 329–334.
- Mihaljević-Peles A, Sagud M, Bozina N, Zivkovic M, Jovanović N. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatr Danub 2010; 22: 335–337.
- Jain KK. Personalized management of neurological disorders. In Textbook of Personalized Medicine, Jain KK (editor), Springer, 2009, p. 255–276.
- De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidon advers drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15–27.
- Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 2004; 9: 442–473.
- Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006; 7: 889–908.
- Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 2008; 18: 157–169.
- Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami, T, Sato Y, Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1230–1234.
- Puzyrev VP, Makeeva OA, Freidin MB. Syntropy, genetic testing and personalized medicine. Personalized Medicine 2010; 7: 399–405.
- Gorwood P, Foot E. Introduction on psychogenetics. In Psychopharmacogenetics, Gorwood P, Hamon M.(editors), New York: Springer Science, 2006, p. 1–21.
- Damjanoska KJ, Van de Kar L.D. Transduction mechanisms: G proteins. In Psychopharmacogenetics, Gorwood P, Hamon M. (editors), New York: Springer Science, 2006, p. 286–314.
- Bartova L, Berger A, Pezawas L. Is there a personalized medicine for mood disorders? Eur Arch Psychiatry Clin Neurosci 2010; 260 (Suppl 2): S121–S126.
- Sokoloff P, Leriche L, Bernard LF. Dopamine receptors: Structure, function and implication in psychiatric disorders. In Psychopharmacogenetics, Gorwood P, Hamon M.(editors) New York, Springer Science, 2006, p. 357–392.